THE ANGELS LOS, KAL. — May 19, 1998 — Researchers in University California-San Francisco report that new hormone therapy reduces the risk a breast cancer in woman 70 percents.

“Our information are much agitated since they show that this can be possible to prevent the breast cancer in postmenopausal woman, who have not preceding history disease,” said Steven Cummings, MD, professor UCSF medicine and epidemic and leaden author of the analysis.

Cummings Presented his(its) information on annual meeting American Society Clinical Oncology yesterday.

THE RESEARCHERS UCSF found that Eli Lilly and medicine osteoporosis preventions Co s, Evista (raloxifene), sharply reduced risk breast cancer in postmenopausal woman not indicating increased risk endometrial, or uterine cancer. The Other medicine in class raloxifene’s, including tamoxifen, are shown to enlarge the risk endometrial cancer in woman.

Though tamoxifen recently report that reduce the risk a breast cancer in woman, who - in high risk disease 45 percents, this also shown the increased risk endometrial cancer. 13,388 Womans, who participated in analysis tamoxifen, 33 those, got the medicine developed endometrial cancer, in contrast with 14 womans fixed in placebo.

Raloxifene And tamoxifen to belong to the class a medicine convened selective estrogen modulators of the receptor (SERMS), which block the actions estrogen on little fabric such as, bosom, and simulator estrogen on other  such as, bones.

“During clinical trial of raloxifene, we saw the double of the events breast cancer to work amongst womans, taking placebo in contrast with that taking raloxifene,” Cummings said.

After average 33 months, 32 events breast cancer designed in woman, who participated in analysis. While 21 or .82 percent of the womans, who were given placebo developed the breast cancer, only 11 or .21 percent that appointed to raloxifene developed disease. However, like tamoxifen and estrogen, Cummings has said that raloxifene enlarges the feminine risk to develop the blood clot.

He has added raloxifene also reduced risk positive breast cancer estrogen- receptor in participation of the womans 87 percents and did not influence upon risk of the negative cancer estrogen- receptor.

Aproximately two-thirds breast cancer in postmenopausal woman - estrogen- receptor positive. This cancer tumours’ cells contains the protein, or receptor, which on estrogen, stimulates growing fabrics in feminine bosom, which can enlarge her(its) risk a breast cancer.

During called on analysis UCSF, 7,705 postmenopausal womans up to age 80 years (the average age 66.5 years), which has osteoporosis and no history bosom or endometrial cancer was arbitrarily nominated to get or 60 or 120 milligrammes per diem raloxifene or matching dose placebo. The Double of the womans was given raloxifene as that in controlling group, which got placebo.

The Cancer of the skin to Exclude, breast cancer is most general form of the cancer amongst women(woman), explaining one of each three cancers are diagnosed in United Staff. Aproximately one in nine womans will develop the breast cancer during her(its) whole life, and is evaluated that disease will press 178,000 womans in USA this year and is killed 43,500.

Since breast cancer can take five or more years to become detectable, Cummings said that analysis will remain during at least once other four years to define the long-term advantage over raloxifene in woman. He has added that women(woman), who participate in clinical test to do the enormous contribution to fight against breast cancer.

“If we remain to see the positive results from analysis, as we expect, women(woman), who worried doggy style bosom must address to their doctor about independently raloxifene - a processing, which they must consider,” Cummings said.

Raloxifene Unique on other SERMS such as, tamoxifen since this has positive, estrogen-like effect on woman bones and cholesterol level until имитирует the disadvantage effects estrogen’s in her(its) bosom and womb. Estrogen Acts linking in structures convened receptors in different target cell fabrics, what then stimulate other answers. The Hormone can cause the growing fabrics in feminine bosom and uterine lining and, time, can enlarge her(its) risk a bosom or endometrial cancer.

At the same time, however, estrogen is proved to vastly reduce the feminine risk osteoporosis and can reduce her(its) risk of the heart disease. Raloxifene Was Approved for prevention osteoporosis Food and Administration Medicine in December 1997.

Tags: Evista, Raloxifene

This entry was posted on Понедельник, Декабрь 28th, 2009 at 15:50 and is filed under Woman Health, Woman health articles. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.